Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.
Curr Oncol
December 2024
Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC.
View Article and Find Full Text PDFA feasibility randomized controlled trial of an individually delivered, peer support intervention to reduce the impact of psychosis stigma and discrimination for people with psychosis: the let's talk study.
Psychol Med
December 2024
The Psychosis Research Unit, Department of Psychology, Greater Manchester Mental Health NHS Foundation Trust, Prestwich, M25 3BL, UK.
Background: Stigma of mental health conditions hinders recovery and well-being. The Honest, Open, Proud (HOP) program shows promise in reducing stigma but there is uncertainty about the feasibility of a randomized trial to evaluate a peer-delivered, individual adaptation of HOP for psychosis (Let's Talk).
Methods: A multi-site, Prospective Randomized Open Blinded Evaluation (PROBE) design, feasibility randomised controlled trial (RCT) comparing the peer-delivered intervention (Let's Talk) to treatment as usual (TAU).
Novel insights into the circ_0003489/let-7b-5p/GLUT1 axis and its possible role in multiple myeloma.
Transpl Immunol
December 2024
Department of Pharmacy, Zhongshan Hospital Xiamen University, Xiamen 361004, Fujian, China. Electronic address:
Background: Circular RNAs (circRNAs) act as vital players in multiple myeloma (MM). Herein, we focused on the function of hsa_circ_0003489 (circ_0003489) in MM development and bortezomib (BTZ) resistance.
Methods: Relative RNA levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR).
Synergic Integration of the miRNome, Machine Learning and Bioinformatics for the Identification of Potential Disease-Modifying Agents in Obstructive Sleep Apnea.
Arch Bronconeumol
December 2024
Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Electronic address:
Introduction: Understanding the diverse pathogenetic pathways in obstructive sleep apnea (OSA) is crucial for improving outcomes. microRNA (miRNA) profiling is a promising strategy for elucidating these mechanisms.
Objective: To characterize the pathogenetic pathways linked to OSA through the integration of miRNA profiles, machine learning (ML) and bioinformatics.
MicroRNA networks in prolactinoma tumorigenesis: a scoping review.
Cancer Cell Int
December 2024
Research Center for Evidence-based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Prolactinoma is the leading type of pituitary adenoma. Aside from the mass-like effect of prolactinoma, its hormonal effect is the main pathological cause of endocrine dysregulation and infertility. The dopamine agonist administration and surgical resection are the current mainstream anti-neoplastic treatments for affected patients; however, tumor fibrosis, tumor invasion, dopamine agonist resistance, and gain prolactinomas are clinical challenges for treating affected patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!